Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Spectral AI Inc (MDAIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: MDAIW (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 78.2% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.7 | 52 Weeks Range 0.09 - 0.90 | Updated Date 06/28/2025 |
52 Weeks Range 0.09 - 0.90 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -30.75% | Operating Margin (TTM) -13.36% |
Management Effectiveness
Return on Assets (TTM) -18.42% | Return on Equity (TTM) -2308.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 17924135 |
Shares Outstanding - | Shares Floating 17924135 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Spectral AI Inc
Company Overview
History and Background
Spectral AI Inc. focuses on developing and commercializing diagnostic tools using its DeepViewu00ae System for burn and wound care assessment. Founded to address the limitations of current methods in assessing tissue viability.
Core Business Areas
- Burn and Wound Assessment: Development and commercialization of the DeepViewu00ae System, an AI-driven imaging platform for assessing burn and wound severity and predicting healing outcomes.
- Diagnostic Imaging: Focus on spectral imaging technology for non-invasive tissue characterization and diagnostic support in clinical settings.
Leadership and Structure
Key personnel include the CEO, CFO, and Chief Medical Officer. The organizational structure is centered around R&D, commercialization, and clinical operations.
Top Products and Market Share
Key Offerings
- DeepViewu00ae System: The flagship product, utilizing spectral imaging and AI to assess burn depth and predict healing. Limited market share data is publicly available; currently scaling commercial efforts. Primary competitors include visual assessment by clinicians and traditional diagnostic methods such as biopsies, but the DeepView's competitive advantage lies in its potential for enhanced accuracy, reduced healing time, and improved clinical outcomes.
Market Dynamics
Industry Overview
The wound care market is driven by factors such as an aging population, increasing incidence of diabetes, and advancements in wound healing technologies.
Positioning
Spectral AI aims to disrupt the traditional wound care market with its AI-powered diagnostic solution, offering improved accuracy and efficiency compared to existing methods.
Total Addressable Market (TAM)
The global advanced wound care market is estimated to be in the billions of dollars. Spectral AI is positioned to capture a portion of this market by offering a novel diagnostic tool that improves clinical outcomes.
Upturn SWOT Analysis
Strengths
- Proprietary DeepViewu00ae System technology
- AI-powered diagnostic capabilities
- Potential for improved patient outcomes
- Focus on unmet needs in wound care
Weaknesses
- Limited commercial traction to date
- Reliance on regulatory approvals
- Need for clinical validation
- Potential for competition from established players
Opportunities
- Expansion into new wound care applications
- Partnerships with hospitals and clinics
- International market expansion
- Further development of AI algorithms
Threats
- Regulatory hurdles
- Competition from existing wound care products
- Technological advancements by competitors
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- MLND
- SYK
- BSX
Competitive Landscape
Spectral AI's competitive advantage lies in its AI-powered diagnostic technology, which has the potential to improve patient outcomes and reduce healthcare costs. However, the company faces competition from established players with broader product portfolios and larger sales forces.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company being in the early stages of commercialization.
Future Projections: Future growth depends on the successful commercialization of the DeepViewu00ae System and expansion into new markets. Analyst estimates are not widely available due to limited coverage.
Recent Initiatives: Recent initiatives include securing regulatory approvals, establishing partnerships with hospitals, and expanding the sales and marketing team.
Summary
Spectral AI is a nascent company with promising AI-driven wound care technology, facing both opportunities and challenges. Its strength lies in its innovative DeepView system, aiming to disrupt traditional wound assessment. However, it needs to scale commercialization and secure clinical validations to compete effectively against larger, established competitors. Regulatory hurdles and market acceptance remain critical considerations for future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data and analyst estimates are subject to change. Please note that the market share percentages are based on broader market classifications and are estimates. Actual market share figures may vary. Financial and Shareholder data are not available publicly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Spectral AI Inc
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2021-04-05 | Co-Founder, Chief Innovation Strategist & Senior Advisor to the CEO Mr. Wensheng Fan | ||
Sector Healthcare | Industry Medical Devices | Full time employees 78 | Website https://www.spectral-ai.com |
Full time employees 78 | Website https://www.spectral-ai.com | ||
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. Its product, DeepView System, uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye, at the initial time point of wound presentation; and delivers a binary prediction on the wounds capacity to heal or not heal by a specified time point in the future to assist the physician in making a more accurate, timely and informed decision regarding the treatment of the patient's wounds. The company's system also includes MSI imaging technology, a proprietary multi-spectral optics and sensors, capturing injured tissue images; and AI-Burn software. Spectral AI, Inc. is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.